We present 2 cases of acute coronary syndrome in patients with concomitant neoplastic disease during chemotherapy. In both patients, we found unusual angiographic image which showed that despite the presence of very large thrombi, there were no or hardly any atherosclerotic lesions in the vessel occlusion site. Aspiration thrombectomy was successfully performed in both cases to restore coronary flow and in the second patient, two bare metal stents were also implanted. After the patients were discharged from hospital, we decided to add enoxaparin to the routine dual antiplatelet therapy of both of them. So far, no guidelines have been developed on how to manage patients with acute coronary syndrome and concomitant neoplastic diseases while on chemotherapy.
INTRODUCTION
Acute coronary syndrome (ACS) is usually caused by atherosclerosis which leads to endothelial dysfunction and secondary increase in coagulation and activation of platelets. Recently, due to population ageing and a better control of cardiovascular risk factors, the percentage of patients suffering from ACS and a concomitant neoplastic disease has been on the rise. It is well known that cancer and chemotherapy increase coagulation and risk of ACS respectively. In this group of patients, we may frequently find unusual clinical and angiographic image, which requires an individual approach. No guidelines exist on how to manage these patients (with ACS and neoplastic diseases) and usually they receive routine ACS treatment, i.e. primary percutaneous coronary intervention (PPCI) with stent implantation and 12 months of dual antiplatelet therapy (DAPT) [1, 2] .
In the article, we present 2 patients with a neoplastic disease and ACS which occurred during chemotherapy. In both cases, a large thrombus formation was the cause of ACS. Both interventions were preceded by an administration of loading doses of heparin, DAPT, GP IIb/IIIa inhibitors infusion and aspiration thrombectomy. Later, two different clinical scenarios were carried out.
PRESENTATION OF THE CASES Patient 1.
A 64-year-old man with a history of coronary disease and diabetes type 2, 16 years after coronary artery bypass surgery (CABG) and concomitant prostate cancer with bones metastases had been treated for 2.5 years with palliative chemotherapy which included leuprorelin 22.5 mg, zoledronic acid 4 mg and bicalutamide 50 mg.
The patient was hospitalized for inferior nSTEMI. Cardiac markers values were: TnT 133 ng/ml (normal value < 14 ng/l), CK-MB 139 ng/ml (normal value < 3.77 ng/ml). 
Patient 2.
A 35-year-old man presented with anterior STEMI 2 months after orchidectomy due to testicular seminoma and directly after the first course of chemotherapy with bleomycin 30 mg, etoposide 210 mg, cisplatin 42 mg and prednisone 10 mg. At admission, TnI was 3.6 ng/ml (normal value < 0.033 ng/ml), CK-MB mass 24.5 ng/ml (normal value < 6.6 ng/ml).
Coronary angiography revealed a large thrombus in the proximal and mid-left anterior descending artery (LAD) as a culprit lesion, and no changes in other arteries. Before the intervention, the patient was treated with abciximab i.c., heparin i.v., and Acute coronary syndrome in patients with concomitant neoplastic disease and chemotherapy. Is clinical distinctness possible?
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